While early studies have indicated that the proinvasive effect of EZH2 requires a functional SET domain [62], there is now increasing evidence that EZH2 is capable of transactivating target genes involved in cellular proliferation such as c-myc and cyclin D1 independent of its SET domain by physically interacting with receptor-mediated pathways in cancer cells [63]. Here, CCND1 is linked to cancer.